At Innoforce, we accept different formulations, or you could choose Innoforce's proprietary formulation to encapsulate your mRNA. Through our testing of different formulations, encapsulation efficiencies as high as 98% are achievable. Innoforce’s mRNA platform is highly stable and robust, with low deviations seen from batch to batch.

The complexity of the LNP structure significantly influences the stability of LNP products. Problems in process or formulation can lead to incomplete encapsulation or instability of these LNP products. Innoforce’s proven LNP platform provides high stability of LNP drug products, as demonstrated by testing freeze-thaw stability and storage stability under different temperatures. The results demonstrated good freeze-thaw stability after five cycles and good storage stability at -80℃, -20℃, 2-8℃, and 25℃.

When mRNA therapy is utilized for gene therapy or protein replacement, a high concentration of mRNA is required. However, sharp decreases in LNP encapsulation efficiency tend to occur as mRNA concentrations increase. Innoforce has developed a proprietary technology to address this critical issue plaguing the industry, thus allowing excellent LNP encapsulation efficiencies even with high mRNA concentrations.